Products AN2690 + AN2690 + AN2690
AN2690 + AN2690 + AN2690 Phase 1 Completed 💤 Quiet Interest: 29/100
Jan 22, 2007 → Feb 19, 2007
About AN2690 + AN2690 + AN2690 AN2690 + AN2690 + AN2690 is a phase 1 stage product being developed by Pfizer for Onychomycosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00680095. Target conditions include Onychomycosis.
What happened to similar drugs? 2 of 10 similar drugs in Onychomycosis were approved
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT00680095 Phase 1 Completed Jan 22, 2007 Feb 19, 2007 Onychomycosis
Product Company Stage Hype Score NVXT Solution + Vehicle of test product Sun Pharmaceutical Phase 2 NVXT topical + Placebo (Vehicle) Topical Sun Pharmaceutical Phase 2 SCH 56592 + SCH 56592 + SCH 56592 + SCH 56592 + Terbinafine + Placebo Merck Phase 2 terbinafine + Placebo + terbinafine + Placebo Novartis Phase 3 terbinafine hydrogen chloride + amorolfine nail lacquer Novartis Phase 3 terbinafine + Placebo + terbinafine + Placebo Novartis Phase 3 AN2690 Pfizer Phase 2 AN2690, 2.5% + AN2690, 5% + AN2690, 7.5% + Vehicle Pfizer Phase 2 AN2690 Solution, 5.0% + AN2690 Solution, 7.5% Pfizer Phase 2 AN2690 Topical Solution, 5% + Solution Vehicle Pfizer Phase 3 AN2690 + AN2690 Pfizer Phase 2 Tavaborole 5% Topical Solution Pfizer Approved AN2690 Solution, 5.0% Pfizer Phase 2 AN2690, 2.5% + AN2690, 5% + AN2690, 7.5% + AN2690 Solution Vehicle Pfizer Phase 2 AN2690 Pfizer Phase 2 AN2690 Topical Solution, 5% + Solution Vehicle Pfizer Phase 3 Albaconozole + Placebo + Albaconozole + Placebo + Albaconozole + Placebo GSK plc Phase 1 Itraconazole 100mg capsules + Itraconazole 200mg tablets + Placebo tablets GSK plc Phase 3 Albaconazole tablet 400mg + Albaconazole 100mg capsules, then albaconazole 400mg tablet GSK plc Phase 1 Albaconazole 100mg + Albaconazole 200mg + Albaconazole 400mg + Albaconazole 400mg + Placebo 400 mg GSK plc Phase 2